BCMA CAR-T Cell Binding Design for Broad B-Cell Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for treating diseases associated with pathogenic B cells, such as multiple myeloma and non-Hodgkin's lymphoma, face challenges due to treatment resistance and the need for alternative target structures, particularly when anti-CD19 CARs fail, and existing anti-BCMA CARs lack reactivity against a diverse range of B-NHLs.
Innovation Solution
A chimeric antigen receptor (CAR) polypeptide is developed with a specific antigen-binding domain that targets the B Cell Maturation Antigen (BCMA), comprising a variable heavy chain (VH) and light chain (VL) with high affinity and specificity, allowing T cells to recognize and destroy BCMA-expressing cells, including those with low antigen levels, and is configured with various signaling domains for flexibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing anti-BCMA CARs are used, then some B cell malignancies can be targeted, but they lack reactivity against a diverse range of B-NHLs
Solution Approach 1:
The patent modifies the antigen-binding domain parameters by selecting specific variable heavy chain (VH) and variable light chain (VL) sequences with optimized affinity and specificity characteristics. This parameter optimization enables the CAR to recognize and bind to BCMA across diverse B-NHL subtypes while maintaining reliable treatment effectiveness.
2Manufacturing precision
If CAR-T cells are designed to target BCMA with high affinity, then tumor cells with low antigen levels can be killed, but off-target reactivity may increase
Solution Approach 1:
The patent applies local quality by engineering the antigen-binding domain with specific VH and VL sequences that are optimized for high affinity and specificity toward BCMA. This localized optimization of binding characteristics at the molecular level enables precise targeting of tumor cells with low antigen levels while minimizing off-target reactivity through careful selection of complementarity-determining regions.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and/or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody- dependent autoimmune diseases.